

NEWS RELEASE



Provista Diagnostics, Inc. Joins AdvaMed Dx

SCOTTSDALE, AZ – June 07, 2014 – Provista is pleased to announce that is now a proud member of AdvaMed Dx.

About AdvaMed Dx

AdvaMed Dx member companies produce advanced, in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMed Dx is the only multi-faceted, policy organization that deals exclusively with issues facing in vitro diagnostic companies both domestically in the United States and abroad. For more information, visit: www.advamed.org and www.advameddx.org.

About Provista Diagnostics, Inc.

Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing blood based, proprietary diagnostic, prognostic and monitoring tests for cancers affecting women, including breast, ovarian, and other gynecologic malignancies. Tests are performed in Provista's high complexity clinical laboratory, which is licensed in 49 states and is certified by the Centers for Medicare & Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA) and is accredited by the College of American Pathologists. Additional information about Provista Diagnostics is available at www.ProvistaDx.com.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen

risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Contact

David R. Holmes
Provista Diagnostics, Inc.
HolmesD@ProvistaDx.com
(212) 202-3170

###